Characteristics of the Included Studies
| Study | Design | Patients | Intervention/ Control |
Study duration (wk) |
Dosage (mg/day) | Pain measure scales |
|---|---|---|---|---|---|---|
| Cardenas et al. [44] Chile, China, Columbia, Czech Republic, Hong Kong, India, Japan, Philippines, Russian Federation, USA |
Parallel | 111 PGB, 108 PBO |
PGB/PBO | 17 | PGB: 150–600 PBO: 150–600 |
DAAC |
| Kaydok et al. [45] Turkey |
Crossover | 28 | PGB/GBP | 8 | PGB: 150–600 GBP: 300–3,600 |
VAS, NPS |
| Levendoglu et al. [40] Turkey |
Crossover | 20 | GBP/PBO | 20 | GBP: 900–3,600 PBO: - |
VAS, NPS |
| Rintala et al. [42] USA |
Crossover | 38 | GBP/PBO | 8 | GBP: 100–1,200 PBO: 25 |
VAS, NRS |
| Siddall et al. [41] Australia |
Parallel | 70 PGB, 67 PBO |
PGB/PBO | 12 | PGB: 150–600 PBO: 150–600 |
VAS |
| Tai et al. [39] USA |
Parallel | 7 | GBP/PBO | 4 | GBP: 300–1,800 PBO: 300–1,800 |
NPS |
| Vranken et al. [43] Netherlands |
Parallel | 11PGB, 10 PBO |
PGB/PBO | 4 | PGB: 150–600 PBO: - |
VAS |
| Yilmaz et al. [46] Turkey |
Crossover | 21 | PGB/GBP | 16 | PGB: up to 300 GBP: up to 1,800 |
VAS |
PGB: pregabalin, PBO: placebo, DAAC: duration-adjusted average change, GBP: gabapentin, VAS: visual analog scale, NPS: neuropathy pain scale, NRS: numeric rating scale.